See more : Acer E-Enabling Service Business Inc. (6811.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Quanta, Inc. (QNTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quanta, Inc., a leading company in the Household & Personal Products industry within the Consumer Defensive sector.
You may be interested
- TECO Electric & Machinery Co., Ltd. (1504.TW) Income Statement Analysis – Financial Results
- bioAffinity Technologies, Inc. (BIAF) Income Statement Analysis – Financial Results
- Onward Technologies Limited (ONWARDTEC.BO) Income Statement Analysis – Financial Results
- Candles Scandinavia AB (publ) (CANDLE-B.ST) Income Statement Analysis – Financial Results
- Hung Chou Fiber Ind. Co., Ltd (1413.TW) Income Statement Analysis – Financial Results
Quanta, Inc. (QNTA)
About Quanta, Inc.
Quanta, Inc., an applied science company, provides pharmaceutical, nutraceutical, topical relief, and cosmetic products in the United States. The company offers contract research services, including research, development, and production of pharmaceutical-grade products, as well as clinical evidence-based nutraceuticals utilizing patented polarization technology. It also manufactures and distributes consumer wellness products in areas of pain relief, beauty, and general wellness. The company was founded in 2016 and is headquartered in Burbank, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Revenue | 673.41K | 1.16M | 1.27M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 143.42K | 281.27K | 303.72K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 529.98K | 876.85K | 965.27K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 78.70% | 75.71% | 76.07% | 0.00% | 0.00% | 0.00% |
| Research & Development | 453.50K | 452.44K | 351.67K | 85.00K | 74.00K | 4.40K |
| General & Administrative | 7.88M | 5.56M | 6.10M | 93.95K | 54.99K | 14.86K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.88M | 5.56M | 6.10M | 93.95K | 54.99K | 14.86K |
| Other Expenses | 390.71K | -381.08K | -238.40K | 0.00 | 4.00K | 0.00 |
| Operating Expenses | 8.33M | 6.01M | 6.45M | 178.95K | 132.99K | 19.26K |
| Cost & Expenses | 8.48M | 6.29M | 6.76M | 178.95K | 132.99K | 19.26K |
| Interest Income | 0.00 | 0.00 | 37.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 584.78K | 1.27M | 226.24K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 153.06K | 342.89K | 261.07K | 161.14K | 4.00K | 22.82K |
| EBITDA | -7.65M | -5.39M | -5.23M | -178.95K | 0.00 | 0.00 |
| EBITDA Ratio | -1,135.93% | -413.42% | -411.88% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.80M | -5.13M | -5.49M | -178.95K | -132.99K | -19.26K |
| Operating Income Ratio | -1,158.66% | -443.03% | -432.46% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -450.65K | -2.78M | -299.54K | 0.00 | 311.95K | 0.00 |
| Income Before Tax | -8.25M | -8.16M | -5.79M | -178.95K | -132.99K | -19.26K |
| Income Before Tax Ratio | -1,225.58% | -704.98% | -456.06% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 584.78K | 1.27M | 226.24K | 357.91K | 265.99K | 0.00 |
| Net Income | -8.84M | -9.43M | -6.01M | -178.95K | -132.99K | -19.26K |
| Net Income Ratio | -1,312.42% | -814.50% | -473.89% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.16 | -0.14 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.04 | -0.16 | -0.14 | -0.01 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 224.02M | 59.91M | 42.81M | 19.78M | 22.00M | 22.00M |
| Weighted Avg Shares Out (Dil) | 224.02M | 59.91M | 42.81M | 19.78M | 22.00M | 22.00M |
Astera Labs Extends Interoperability Leadership Driving Seamless PCIe 6.x Deployment
SANTA CLARA, Calif.--(BUSINESS WIRE)--Astera Labs (Nasdaq: ALAB), a global leader in semiconductor-based connectivity solutions for AI and cloud infrastructure, today announced expanded PCIe® 6.x testing capabilities in its Cloud-Scale Interop Lab to enable seamless interoperability between Aries 6 PCIe/CXL Smart...
Astera Labs 持續擴展互通性領先地位，推動無縫接軌 PCIe 6.x 部署
美國加利福尼亞州聖塔克拉拉--(BUSINESS WIRE)--(美國商業資訊)-- 為 AI 和雲端基礎結構提供半導體連線解決方案的全球領導者 Astera Labs (Nasdaq: ALAB) 今日宣布擴展其 Cloud-Scale Interop Lab 的 PCIe 6.x 測試能力，以實現 Aries 6 PCIe/CXL Smart DSP Retimers 與廣泛的 PCIe 6.x 主機和端點之間的無縫互通性。這為人工智慧平臺開發人員設計高頻寬、低延遲的 PCIe 6.x 連線鋪平了道路，減少了整體開發時間，並有助於實現大規模部署。 Astera Labs 首席商務官 Thad Omura表示：“隨著人工智慧系統的不斷快速發展，資料中心運營商需要在更短的時間內部署日益複雜的系統。我們對於標準合規性和隨插即用互通性的高度重視，是我們廣泛部署並經過現場測試的 Aries Retimer 組合能夠成為 PCIe/CXL 連線黃金標準的根本原因。擴展我們的...
Quanta Services Selected for Colorado's Power Pathway Transmission Project
Project Expected to Extend Through 2027, Supporting Multi-Year Visibility and Growth Opportunities HOUSTON , Dec. 22, 2022 /PRNewswire/ -- Quanta Services, Inc. (NYSE: PWR) announced today that it has been selected by Xcel Energy as its prime constructor to manage...
Is Quanta a Better Engineering R&D Services Pick Than Jacobs?
The U.S. administration's focus on enhancing the country's infrastructure is likely to boost the demand for engineering and infrastructure service providers. Let us analyze which is a better pick - PWR or J.
Medolife Rx Schedules Conference Call with Investment Community To Discuss Third Quarter 2021 Financial and Operational Results and New Updates
BURBANK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today...
Stocks This Week: Buy Quanta Services And Valero
Stocks are likely to rise late in the week.
Medolife Rx Announces that the Government of the Dominican Republic is Willing to Include Escozine into its COVID-19 Treatment Regimen
BURBANK, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that...
Medolife Rx Reports 257% Increase in Efficacy of Ibuprofen Through Proprietary Polarization Method, Looks to Expand Into Other APIs
BURBANK, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today...
Medolife Rx Initiates Comparative Study of Its Flagship CBD-based Muscle Rub and Competitor
BURBANK, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today...
Medolife Rx Files Bi-Annual Report With Ministry of Environment in the Dominican Republic, Details Reservation Expansion and Exceeds Regulatory Expectations
BURBANK, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today...
Source: https://incomestatements.info
Category: Stock Reports